title: Treatment of Alzheimer's disease: an evaluation of the cholinergic approach.
abstract: The cholinergic hypothesis claims that a decrease of acetylcholine (ACh) in the brain of patients with Alzheimer's Disease (AD) plays an important role in the deterioration of cognitive functioning. This hypothesis has led to extensive research in possible therapeutic approaches towards improving cholinergic transmission in AD patients. The different approaches have focused on the following six strategies: ACh precursors, ACh release, M1, M3, or M4 receptor agonists, M2 receptor antagonists, nicotinic agonists, and acetylcholinesterase inhibitors (AChEI). The aim of this review is to assess the effectiveness of the cholinergic approach for the treatment of AD.
authors.affiliation: Department of Neurology, U.Z. Gasthuisberg, Leuven.
authors.forename: J
authors.initials: J
authors.lastname: Lemière
authors.forename: D
authors.initials: D
authors.lastname: Van Gool
authors.forename: R
authors.initials: R
authors.lastname: Dom
mesh_terms: D000109:Acetylcholine / Q000096:biosynthesis / Q000502:physiology*; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D002219:Carbamates / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D018678:Cholinergic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002799:Cholinergic Fibers / Q000502:physiology; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000077265:Donepezil; D004311:Double-Blind Method; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D018697:Nootropic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D048448:Phenylcarbamates; D010880:Piperidines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011950:Receptors, Cholinergic / Q000187:drug effects*; D011976:Receptors, Muscarinic / Q000145:classification / Q000187:drug effects; D011978:Receptors, Nicotinic / Q000187:drug effects; D000068836:Rivastigmine; D013619:Tacrine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D002219:Carbamates; D018678:Cholinergic Agents; D002800:Cholinesterase Inhibitors; D007189:Indans; D018697:Nootropic Agents; D048448:Phenylcarbamates; D010880:Piperidines; D011950:Receptors, Cholinergic; D011976:Receptors, Muscarinic; D011978:Receptors, Nicotinic; D013619:Tacrine; D000077265:Donepezil; D000109:Acetylcholine; D000068836:Rivastigmine